Get the Stockscreener App
1.38
2.13%
-0.03
After Hours:
1.39
0.01
+0.72%
Ocugen Inc stock is traded at $1.38, with a volume of 12.72M.
It is down -2.13% in the last 24 hours and down -17.86% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$1.41
Open:
$1.41
24h Volume:
12.72M
Relative Volume:
1.45
Market Cap:
$467.16M
Revenue:
$4.41M
Net Income/Loss:
$-67.85M
P/E Ratio:
-6.1116
EPS:
-0.2258
Net Cash Flow:
$-57.15M
1W Performance:
+2.99%
1M Performance:
-17.86%
6M Performance:
+11.29%
1Y Performance:
+65.43%
1-Day Range:
$1.37
$1.415
1-Week Range:
$1.34
$1.43
52-Week Range:
$0.80
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.38 | 477.32M | 4.41M | -67.85M | -57.15M | -0.2258 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Initiated | Canaccord Genuity | Buy |
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Price Target Cut to $11.00/Share From $12.00 by Canaccord Genuity - Moomoo
OCGN Maintained by Canaccord Genuity -- Price Target Lowered to $11 - GuruFocus
Three Speculative Biotech Penny Stocks With Pipeline Catalysts - Kalkine Media
Ocugen Is Maintained at Buy by Canaccord Genuity - Moomoo
Canaccord lowers Ocugen stock price target to $11 on model update By Investing.com - Investing.com South Africa
Canaccord lowers Ocugen stock price target to $11 on model update - Investing.com
CCORF Maintains Ocugen(OCGN.US) With Buy Rating, Cuts Target Price to $11 - Moomoo
FTSE Russell Index Reconstitution Sees Major Changes with Ocugen (OCGN) Joining - GuruFocus
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Ocugen (OCGN) Set for Inclusion in Russell 3000 Index Rebalancin - GuruFocus
OCGN Stock Price, Quote & Chart | OCUGEN INC (NASDAQ:OCGN) - ChartMill
Q4 2025 Ocugen Inc Earnings Call Transcript - GuruFocus
OCGN stock tanks after gene therapy trial update — what did Ocugen announce? - MSN
Ocugen Inc stock (US67577C1053): FDA feedback keeps retinitis pigmentosa trial on track - AD HOC NEWS
Stock Quote & Chart - Ocugen, Inc.
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen closes $130 million convertible notes offering - Investing.com UK
Gene therapy pipeline accelerates as Ocugen, Inc. targets approvals for RP and Stargardt disease - Traders Union
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout
Ocugen Raises $130 Million Through Convertible Notes Offering - TipRanks
Ocugen Announces Interim Chief Medical Officer Appointment Transition - TipRanks
symbol__ Stock Quote Price and Forecast - CNN
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes - Ocugen, Inc.
Ocugen closes $130 million convertible notes offering By Investing.com - Investing.com Australia
Ocugen Reports Positive GA Trial Data, Extends Cash Runway - MyChesCo
Ocugen (NASDAQ: OCGN) shifts CMO duties to interim leader - Stock Titan
Ocugen (NASDAQ: OCGN) closes $130M 6.75% convertible notes due 2034 - Stock Titan
Ocugen signs license deal with Korean company for gene therapy - MSN
Ocugen issues $115M notes to repay debt; stock faces after-hours selling - MSN
Ocugen to Participate in Upcoming May Scientific and Investor Conferences - Sahm
3 Reasons Not to Buy Into the Hantavirus-Related Biotech Rally - The Motley Fool
Ocugen’s Convertible Cash and Reverse Split Vote Set the Table for a Triple-Data Summer - AD HOC NEWS
Ocugen, Inc. to Present Innovative Modifier Gene Therapy Platform at May 2026 Conferences - Quiver Quantitative
Ocugen brings blindness gene therapy to two May events in 2026 - Stock Titan
Ocugen (OCGN) Reports Q1 EPS - Insider Monkey
Ocugen’s Clinical Calendar Packs a Punch in Q3 as Analysts Stay Bullish on Gene Therapy Pipeline - AD HOC NEWS
5 Best Penny Stocks to Buy Before They Explode - Insider Monkey
Ocugen stock (US67577C1053): Q1 2026 earnings miss sparks stock drop - AD HOC NEWS
Ocugen, Inc. advances automation in quantitative autofluorescence for geographic atrophy at ARVO2026 - Traders Union
Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop By Investing.com - Investing.com South Africa
Earnings call transcript: Ocugen Q1 2026 earnings miss triggers stock drop - Investing.com
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):